An Explorative Psoriasis Biomarker Study

NATerminatedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

February 22, 2023

Study Completion Date

March 27, 2023

Conditions
Psoriasis Vulgaris
Interventions
DRUG

Guselkumab

100 mg guselkumab administered subcutaneously

DRUG

Placebos

Sodiumchloride 0,9% solution for injection

Trial Locations (1)

2333 CL

Centre for Human Drug Research, Leiden

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

lead

Centre for Human Drug Research, Netherlands

OTHER